NASDAQ:ADTX

ADiTx Therapeutics Competitors

$2.74
+0.01 (+0.37 %)
(As of 04/14/2021 11:26 AM ET)
Add
Compare
Today's Range
$2.71
Now: $2.74
$2.80
50-Day Range
$2.54
MA: $2.99
$3.74
52-Week Range
$1.62
Now: $2.74
$9.58
Volume954 shs
Average Volume3.21 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

ADiTx Therapeutics (NASDAQ:ADTX) Vs. ABCL, SANA, ABCM, SEER, NUVB, and IBRX

Should you be buying ADTX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to ADiTx Therapeutics, including AbCellera Biologics (ABCL), Sana Biotechnology (SANA), Abcam (ABCM), Seer (SEER), Nuvation Bio (NUVB), and ImmunityBio (IBRX).

AbCellera Biologics (NASDAQ:ABCL) and ADiTx Therapeutics (NASDAQ:ADTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AbCellera Biologics and ADiTx Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbCellera Biologics00503.00
ADiTx Therapeutics00103.00

AbCellera Biologics presently has a consensus price target of $52.80, suggesting a potential upside of 76.94%. Given AbCellera Biologics' higher possible upside, equities analysts plainly believe AbCellera Biologics is more favorable than ADiTx Therapeutics.

Earnings & Valuation

This table compares AbCellera Biologics and ADiTx Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbCellera BiologicsN/AN/AN/AN/AN/A
ADiTx TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares AbCellera Biologics and ADiTx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbCellera BiologicsN/AN/AN/A
ADiTx TherapeuticsN/AN/AN/A

Summary

AbCellera Biologics beats ADiTx Therapeutics on 2 of the 2 factors compared between the two stocks.

ADiTx Therapeutics (NASDAQ:ADTX) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for ADiTx Therapeutics and Sana Biotechnology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADiTx Therapeutics00103.00
Sana Biotechnology02202.50

Sana Biotechnology has a consensus price target of $40.00, suggesting a potential upside of 54.38%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than ADiTx Therapeutics.

Valuation & Earnings

This table compares ADiTx Therapeutics and Sana Biotechnology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADiTx TherapeuticsN/AN/AN/AN/AN/A
Sana BiotechnologyN/AN/AN/AN/AN/A

Profitability

This table compares ADiTx Therapeutics and Sana Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADiTx TherapeuticsN/AN/AN/A
Sana BiotechnologyN/AN/AN/A

Summary

Sana Biotechnology beats ADiTx Therapeutics on 2 of the 3 factors compared between the two stocks.

ADiTx Therapeutics (NASDAQ:ADTX) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for ADiTx Therapeutics and Abcam, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADiTx Therapeutics00103.00
Abcam04302.43

Abcam has a consensus price target of $22.00, suggesting a potential upside of 11.68%. Given Abcam's higher probable upside, analysts clearly believe Abcam is more favorable than ADiTx Therapeutics.

Valuation & Earnings

This table compares ADiTx Therapeutics and Abcam's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADiTx TherapeuticsN/AN/AN/AN/AN/A
AbcamN/AN/AN/AN/AN/A

Profitability

This table compares ADiTx Therapeutics and Abcam's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADiTx TherapeuticsN/AN/AN/A
AbcamN/AN/AN/A

Summary

Abcam beats ADiTx Therapeutics on 2 of the 3 factors compared between the two stocks.

ADiTx Therapeutics (NASDAQ:ADTX) and Seer (NASDAQ:SEER) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for ADiTx Therapeutics and Seer, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADiTx Therapeutics00103.00
Seer02202.50

Seer has a consensus price target of $68.00, suggesting a potential upside of 22.08%. Given Seer's higher probable upside, analysts clearly believe Seer is more favorable than ADiTx Therapeutics.

Valuation & Earnings

This table compares ADiTx Therapeutics and Seer's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADiTx TherapeuticsN/AN/AN/AN/AN/A
SeerN/AN/AN/AN/AN/A

Profitability

This table compares ADiTx Therapeutics and Seer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADiTx TherapeuticsN/AN/AN/A
SeerN/AN/AN/A

Summary

Seer beats ADiTx Therapeutics on 2 of the 3 factors compared between the two stocks.

ADiTx Therapeutics (NASDAQ:ADTX) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Profitability

This table compares ADiTx Therapeutics and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADiTx TherapeuticsN/AN/AN/A
Nuvation BioN/AN/AN/A

Valuation & Earnings

This table compares ADiTx Therapeutics and Nuvation Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADiTx TherapeuticsN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for ADiTx Therapeutics and Nuvation Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADiTx Therapeutics00103.00
Nuvation Bio00603.00

Nuvation Bio has a consensus price target of $17.40, suggesting a potential upside of 50.52%. Given Nuvation Bio's higher probable upside, analysts clearly believe Nuvation Bio is more favorable than ADiTx Therapeutics.

Summary

Nuvation Bio beats ADiTx Therapeutics on 2 of the 2 factors compared between the two stocks.

ADiTx Therapeutics (NASDAQ:ADTX) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Profitability

This table compares ADiTx Therapeutics and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADiTx TherapeuticsN/AN/AN/A
ImmunityBioN/AN/AN/A

Earnings & Valuation

This table compares ADiTx Therapeutics and ImmunityBio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADiTx TherapeuticsN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for ADiTx Therapeutics and ImmunityBio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADiTx Therapeutics00103.00
ImmunityBio00103.00

ImmunityBio has a consensus target price of $25.00, suggesting a potential upside of 37.51%. Given ImmunityBio's higher probable upside, analysts plainly believe ImmunityBio is more favorable than ADiTx Therapeutics.

Summary

ImmunityBio beats ADiTx Therapeutics on 1 of the 1 factors compared between the two stocks.


ADiTx Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AbCellera Biologics logo
ABCL
AbCellera Biologics
1.5$29.12+3.0%$7.62 billionN/A0.00Increase in Short Interest
Sana Biotechnology logo
SANA
Sana Biotechnology
1.2$25.33+4.5%$4.54 billionN/A0.00
Abcam logo
ABCM
Abcam
1.5$19.65+0.1%$4.46 billionN/A0.00News Coverage
SEER
Seer
1.0$54.55+4.3%$3.47 billionN/A0.00Increase in Short Interest
Nuvation Bio logo
NUVB
Nuvation Bio
2.2$11.81+9.5%$2.18 billionN/A0.00Analyst Report
Insider Buying
News Coverage
Gap Down
IBRX
ImmunityBio
1.7$18.45+9.2%$1.83 billionN/A0.00Gap Down
BioAtla logo
BCAB
BioAtla
1.7$45.57+0.9%$1.55 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$36.00+8.3%$1.42 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$35.01+7.8%$1.40 billionN/A0.00
EWTX
Cricut
0.3$28.24+1.3%$1.33 billionN/A0.00
KNTE
Kinnate Biopharma
1.7$29.32+3.2%$1.23 billionN/A0.00Increase in Short Interest
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$36.70+7.1%$1.19 billionN/A0.00Analyst Report
Gap Down
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$31.97+16.9%$1.18 billionN/A0.00Earnings Announcement
Analyst Report
Insider Selling
Increase in Short Interest
News Coverage
Vor Biopharma logo
VOR
Vor Biopharma
1.9$31.76+8.2%$1.08 billionN/A0.00
FDMT
4D Molecular Therapeutics
1.1$37.77+5.4%$954.04 millionN/A0.00Increase in Short Interest
Gap Down
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.0$16.93+0.1%$946.10 millionN/A0.00Analyst Report
News Coverage
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$29.00+0.6%$918.27 millionN/A0.00Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.81+0.4%$908.70 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$24.84+0.5%$876.07 millionN/A0.00Analyst Report
Increase in Short Interest
PHAR
Pharming Group
0.0$12.95+2.3%$845.43 millionN/A0.00Decrease in Short Interest
News Coverage
Gap Up
FNCH
Finch Therapeutics Group
1.3$16.45+3.3%$801.47 millionN/A0.00Analyst Report
News Coverage
Gap Up
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.05+4.7%$798.13 millionN/A0.00Analyst Report
SGTX
Sigilon Therapeutics
1.4$19.51+4.5%$587.03 millionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
1.4$13.75+1.7%$540.43 millionN/A0.00News Coverage
Gap Up
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$11.50+2.3%$506.10 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Up
NexImmune logo
NEXI
NexImmune
2.0$24.96+16.1%$476.78 millionN/A0.00News Coverage
Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$18.71+4.9%$447.23 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.27+0.5%$438.63 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.8$10.77+1.5%$425.65 millionN/A0.00News Coverage
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$14.70+2.8%$421.33 millionN/A0.00
PRTG
Portage Biotech
0.0$28.55+2.5%$353.43 millionN/A0.00
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.85+3.9%$302.37 millionN/A-2.71
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.71+4.2%$299.20 millionN/A-3.04Gap Down
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.61+1.9%$259.23 millionN/A0.00
IPA
ImmunoPrecise Antibodies
0.0$11.15+5.3%$224.46 millionN/A0.00Increase in Short Interest
Gap Up
LBPH
Longboard Pharmaceuticals
1.9$11.86+9.5%$200.64 millionN/A0.00Analyst Report
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$23.57+2.4%$167.63 millionN/A0.00
VINC
Vincerx Pharma
1.0$19.25+1.7%$155.32 millionN/A0.00
GANX
Gain Therapeutics
1.7$13.20+6.1%$149.57 millionN/A0.00Analyst Report
Gap Up
LGVN
Longeveron
0.3$7.37+0.7%$136.94 millionN/A0.00News Coverage
Gap Up
EVAX
Evaxion Biotech A/S
1.7$6.96+6.5%$124.99 millionN/A0.00News Coverage
Gap Down
UPC
Universe Pharmaceuticals
0.0$4.10+0.2%$88.96 millionN/A0.00Gap Down
VRDN
Viridian Therapeutics
1.7$15.66+1.9%$60.07 millionN/A0.00Decrease in Short Interest
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.43+2.4%$54.58 millionN/A0.00Gap Up
VIRI
Virios Therapeutics
1.3$5.85+2.4%$48.73 millionN/A0.00Gap Up
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.34+3.6%$37.93 millionN/A0.00Gap Down
VLON
Vallon Pharmaceuticals
0.3$5.05+1.4%$34.87 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$4.66+1.5%$23.39 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$38.00+3.5%$18.25 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.78+3.4%$14.91 millionN/A0.00
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.